Who are Hyperpolarized 129 Xenon's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hyperpolarized-129-xenon.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hyperpolarized 129 Xenon — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyperpolarized 129 Xenon (Hyperpolarized 129 Xenon) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hyperpolarized noble gas contrast agent. Area: Pulmonology / Respiratory Imaging.

marketed Hyperpolarized noble gas contrast agent Pulmonology / Respiratory Imaging Small molecule Live · refreshed every 30 min

Target snapshot

Hyperpolarized 129 Xenon (Hyperpolarized 129 Xenon) — Children's Hospital Medical Center, Cincinnati. Hyperpolarized 129 xenon is inhaled as a contrast agent for magnetic resonance imaging (MRI) that enhances visualization of lung ventilation and gas exchange.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hyperpolarized 129 Xenon TARGET	Hyperpolarized 129 Xenon	Children's Hospital Medical Center, Cincinnati	marketed	Hyperpolarized noble gas contrast agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hyperpolarized noble gas contrast agent class)

Children's Hospital Medical Center, Cincinnati · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hyperpolarized 129 Xenon — Competitive Intelligence Brief. https://druglandscape.com/ci/hyperpolarized-129-xenon. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing